logo
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Awards & Recognitions
    • Patents
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GalAhead™
      • PDoV-GalNAc
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Corporate Governance
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
      • Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
      • Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
      • Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
      • Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
      • Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
      • Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
      • Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
      • Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead™ Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
      • Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
      • Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
      • Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
      • Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
      • Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
      • Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
      • Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
      • Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
      • Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA
      • MoCo biopharma Sirnaomics more than triples footprint with new HQ
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
EN 简 繁
img img img
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Awards & Recognitions
    • Patents
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GalAhead™
      • PDoV-GalNAc
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Corporate Governance
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
      • Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
      • Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
      • Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
      • Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
      • Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
      • Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
      • Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
      • Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead™ Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
      • Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
      • Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
      • Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
      • Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
      • Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
      • Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
      • Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
      • Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
      • Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA
      • MoCo biopharma Sirnaomics more than triples footprint with new HQ
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
QR
Back to Press Release

Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

2022.08.26

Gaithersburg, MD, USA and Suzhou Biobay, China, August 26, 2022 – Sirnaomics Ltd. (the “Company” or “Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead™ RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases. Among four product candidates developed with GalAhead™, STP144G, which targets Complement Factor B, has entered into an IND enabling study, while the other three—STP146G, STP145G, and STP247G—are moving into candidate nomination stage.

 

Sirnaomics’ proprietary GalNAc-RNAi therapeutic platform, GalAhead™, relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA™ (miniaturized RNAi triggers) and muRNA™ (multi-unit RNAi triggers). mxRNAs are comprised of single ~30 nucleotide long oligonucleotides to downregulate individual genes, while muRNA molecules are comprised of multiple oligonucleotides to silence two or more targets simultaneously.

 

Complement-related diseases are amongst the important therapeutic areas Sirnaomics has selected for developing GalAhead-based treatments. Based on the validation of the mxRNA inhibitor design, with a long-lasting therapeutic activity observed using rodent and non-human primate animal models, the Company has developed three new mxRNA-based and one muRNA-based programs into the therapeutic candidate nomination phase. STP144G, which targets Complement Factor B, is the first drug candidate that has entered into an IND-enabling study and is expected to advance into clinical study in the second half of 2023. STP146G, which targets Complement Component C3, and STP145G, which targets Complement Component C5, have been validated with both primary cell culture and rodent animal models. Sirnaomics has also developed a dual-targeting muRNA drug compound, STP247G, to inhibit both Complement Component C5 and Complement Factor B for the potential treatment of the complement-mediated immunologic disorders. Due to the simplified structure of these drug candidates, the chemistry, manufacturing and control process of the drug product is well established with a favorable toxicological profile.

 

Dr. Dmitry Samarsky, Sirnaomics Chief Technology Officer, commented: “We are highly satisfied with the performance of our proprietary GalAhead platform, which allows us to quickly, reproducibly, and predictably expand and progress our therapeutic pipeline based on this novel technology.”

 

“We are seeing a quick expansion of our product pipeline developed with the GalAhead platform. Our drug candidates are comprised of GalNAc-alike structure and liver hepatocyte targeting property, which enable Sirnaomics to advance into a new frontier to treat complement-related disorders,” said Dr. Patrick Lu, Sirnaomics founder, Chairman of the Board, Executive Director, President and CEO. “We expect that the first drug candidate based on this delivery platform to be in clinical study in the second half of 2023.”

 

About Complement-Related Diseases

Complement is an integral part of the immune system protecting the host organism against invasion and proliferation of various microorganisms. It is also involved in the removal of the body's own damaged and altered cells. Activation of the complement system is a very precise process and it is strictly controlled by regulatory proteins present in both plasma and at host cells' surfaces. The excessive activation of complement proteins is often discovered to be the reason for many diseases. These include e.g. autoimmune diseases, Alzheimer's syndrome, schizophrenia, atypical hemolytic-uremic syndrome, angioedema, macular degeneration, and Crohn's disease. (Adv Clin Exp Med, 2012 Jan-Feb;21(1):105-14).

 

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.

 

CONTACT: 

Dr. Dmitry Samarsky

Chief Technology Officer, Sirnaomics

Email:  DmitrySamarsky@sirnaomics.com

 

Investor Relations:

Nigel Yip

Chief Financial Officer, China, Sirnaomics

Email: NigelYip@sirnaomics.com

 

US Media Contact:

Alexis Feinberg

Tel: +1 203 939 2225

Email:  Alexis.Feinberg@westwicke.com

 

Asia Media Contact:

Bunny Lee

Tel: +852 3150 6707

Email: sirnaomics.hk@pordahavas.com

Previous
Next
logo
Sirnaomics Ltd.

20511 Seneca Meadows Parkway, Suite 200 Germantown, MD 20876, USA

© 2007-2022 by Sirnaomics
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Awards & Recognitions
    • Patents
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GalAhead™
      • PDoV-GalNAc
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Corporate Governance
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
      • Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
      • Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
      • Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
      • Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
      • Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
      • Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
      • Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
      • Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead™ Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
      • Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
      • Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
      • Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
      • Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
      • Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
      • Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
      • Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
      • Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
      • Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA
      • MoCo biopharma Sirnaomics more than triples footprint with new HQ
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us